PE20070768A1 - Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion - Google Patents

Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion

Info

Publication number
PE20070768A1
PE20070768A1 PE2006001189A PE2006001189A PE20070768A1 PE 20070768 A1 PE20070768 A1 PE 20070768A1 PE 2006001189 A PE2006001189 A PE 2006001189A PE 2006001189 A PE2006001189 A PE 2006001189A PE 20070768 A1 PE20070768 A1 PE 20070768A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
alkylene
oxadiazolone
procedures
Prior art date
Application number
PE2006001189A
Other languages
English (en)
Inventor
Patrick Bernardelli
Stefanie Keil
Matthias Urmann
Hans Matter
Wolfgang Wendler
Maike Glien
Karen Chandross
Lan Lee
Corinne Terrier
Herve Minoux
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35809809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070768(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20070768A1 publication Critical patent/PE20070768A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE B ES CR4, N; R1 ES H, HALOGENO, ALQUILO C1-C8, (ALQUILEN C0-C4)-O-(ALQUILEN C0-C4)-H, ENTRE OTROS; R2, R3 Y R4 SON CADA UNO H, HALOGENO, ALQUILO C1-C8, SCH3, CN, ENTRE OTROS; X ES O, S, SO, O-CH2, SCH2, CH2-S, ENTRE OTROS; W ES ENLACE, ALQUILENO C1-C8, ALQUENILENO C2-C8, CICLOALQUILEN C3-C6, ALQUILENO C1-C6, ENTRE OTROS; Y ES O, S, SO2, NH, ENTRE OTROS; R5 ES H, ALQUILO C1-C8, (ALQUILEN C0-C4)-ARILO, (ALQUILEN C0-C4)-HETEROCICLILO, ENTRE OTROS; Z ES UN ENLACE, ALQUILENO C1-C8, ALQUENILENO C2-C8, ALQUILIDENO C2-C8, ENTRE OTROS; R7 Y R8 SON CADA UNO H, HALOGENO, ALQUILO C1-C8, SCF3, SF5, NO2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-{2-METOXI-4-[2-(4-TRIFLUOROMETIL-FENIL)-4-(4-TRIFLUOROMETIL-PIPERIDIN-1-ILMETIL)-TIAZOL-5-ILMETOXI]-FENIL}-4H-[1,2,4]OXADIAZOL-5-ONA; 3-{2-METOXI-4-[4-MORFOLIN-4-ILMETIL-2-(4-TRIFLUOROMETIL-FENIL)-TIAZOL-5-ILMETOXI]-FENIL}-4H-[1,2,4]OXADIAZOL-5-ONA; ENTRE OTROS. DICHOS COMPUESTOS SON AGONISTAS DE PPAR-alfa UTILES EN LA PREVENCION Y TRATAMIENTO DE DIABETES TIPO II Y LA ATERIOSCLEROSIS
PE2006001189A 2005-09-29 2006-09-29 Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion PE20070768A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05021235 2005-09-29

Publications (1)

Publication Number Publication Date
PE20070768A1 true PE20070768A1 (es) 2007-08-22

Family

ID=35809809

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006001178A PE20070545A1 (es) 2005-09-29 2006-09-28 Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo como agentes moduladores de ppar, composiciones farmaceuticas que los contienen y procedimientos para su preparacion
PE2006001189A PE20070768A1 (es) 2005-09-29 2006-09-29 Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006001178A PE20070545A1 (es) 2005-09-29 2006-09-28 Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo como agentes moduladores de ppar, composiciones farmaceuticas que los contienen y procedimientos para su preparacion

Country Status (31)

Country Link
US (3) US7834030B2 (es)
EP (2) EP1934206B1 (es)
JP (2) JP5183479B2 (es)
KR (2) KR20080048520A (es)
CN (2) CN101268069A (es)
AR (2) AR056541A1 (es)
AT (1) ATE537167T1 (es)
AU (2) AU2006299086A1 (es)
BR (2) BRPI0616465A2 (es)
CA (2) CA2624093A1 (es)
CR (1) CR9784A (es)
CY (1) CY1113376T1 (es)
DK (1) DK1931660T3 (es)
DO (2) DOP2006000205A (es)
EC (1) ECSP088323A (es)
ES (1) ES2392181T3 (es)
IL (2) IL190227A (es)
MA (2) MA29807B1 (es)
MY (2) MY148982A (es)
NO (2) NO20081367L (es)
NZ (2) NZ566875A (es)
PE (2) PE20070545A1 (es)
PL (1) PL1931660T3 (es)
PT (1) PT1931660E (es)
RU (2) RU2008112202A (es)
SI (1) SI1931660T1 (es)
TN (1) TNSN08145A1 (es)
TW (2) TWI398436B (es)
UY (2) UY29830A1 (es)
WO (2) WO2007039172A1 (es)
ZA (1) ZA200801630B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586573B1 (en) * 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2008046135A1 (en) 2006-10-16 2008-04-24 Bionomics Limited Novel anxiolytic compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
US10793515B2 (en) * 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
JP2013503135A (ja) 2009-08-26 2013-01-31 サノフイ 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012116415A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012151640A1 (en) 2011-05-12 2012-11-15 Bionomics Limited Methods for preparing naphthyridines
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013108800A1 (ja) 2012-01-18 2013-07-25 第一三共株式会社 置換フェニルアゾール誘導体
CN104640442A (zh) 2012-06-14 2015-05-20 巴斯夫欧洲公司 使用取代3-吡啶基噻唑化合物和衍生物防除动物有害物的灭害方法
US10258672B2 (en) 2014-10-09 2019-04-16 Case Western Reserve University Compositions and methods of treating root avulsion injury
CN106616029B (zh) * 2016-12-08 2020-05-01 西南大学 一种提高虹鳟抗病能力的饲料添加剂及其制备方法
CN108976150B (zh) * 2017-06-05 2022-11-18 重庆博腾制药科技股份有限公司 一种3-乙基-4-氟苯腈的制备方法
EP3651785A4 (en) * 2017-07-11 2021-07-07 Case Western Reserve University COMPOSITIONS AND METHODS OF TREATMENT OF MYELIN DISEASES
JP7417318B1 (ja) 2022-12-28 2024-01-18 Ｔｈｒｅｅ Ｒｉｖｅｒｓ株式会社 濾過器及び飲料抽出器

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
EP1194147B1 (en) * 1999-06-18 2007-01-10 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
CA2457054C (en) * 2001-08-10 2011-10-11 Nippon Chemiphar Co., Ltd. Activator of peroxisome proliferator-activated receptor .delta.
ATE369855T1 (de) * 2002-02-25 2007-09-15 Lilly Co Eli Modulatoren von peroxisome proliferator- aktivierten rezeptoren
WO2004080943A1 (ja) 2003-03-11 2004-09-23 Ono Pharmaceutical Co., Ltd. シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
JPWO2005054213A1 (ja) 2003-12-02 2007-12-06 塩野義製薬株式会社 ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
EP1586573B1 (en) * 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
RU2375358C2 (ru) * 2004-04-01 2009-12-10 Авентис Фармасьютикалз, Инк. 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение

Also Published As

Publication number Publication date
NZ566875A (en) 2010-06-25
CY1113376T1 (el) 2016-06-22
JP2009509986A (ja) 2009-03-12
SI1931660T1 (sl) 2012-12-31
MA29804B1 (fr) 2008-09-01
ECSP088323A (es) 2008-04-28
DOP2006000204A (es) 2007-03-31
JP2009509989A (ja) 2009-03-12
KR101342415B1 (ko) 2013-12-17
CA2624105A1 (en) 2007-04-12
TW200728293A (en) 2007-08-01
AR056203A1 (es) 2007-09-26
DK1931660T3 (da) 2012-11-05
CN101273036A (zh) 2008-09-24
CA2624093A1 (en) 2007-04-12
CR9784A (es) 2008-05-05
IL190227A0 (en) 2009-09-22
MA29807B1 (fr) 2008-09-01
JP5183479B2 (ja) 2013-04-17
UY29830A1 (es) 2007-04-30
US20080262036A1 (en) 2008-10-23
WO2007039178A2 (en) 2007-04-12
NO20081367L (no) 2008-06-13
EP1934206A1 (en) 2008-06-25
AU2006299092A1 (en) 2007-04-12
US20080287409A1 (en) 2008-11-20
RU2008112202A (ru) 2009-10-10
NO20081370L (no) 2008-06-17
WO2007039178A3 (en) 2007-09-13
US20090281084A1 (en) 2009-11-12
UY29829A1 (es) 2007-04-30
EP1931660A2 (en) 2008-06-18
RU2008112201A (ru) 2009-10-10
KR20080048494A (ko) 2008-06-02
MY149182A (en) 2013-07-31
NZ566878A (en) 2010-07-30
ZA200801630B (en) 2009-01-28
EP1934206B1 (en) 2011-12-14
AU2006299086A1 (en) 2007-04-12
CA2624105C (en) 2014-02-18
PL1931660T3 (pl) 2012-12-31
ES2392181T3 (es) 2012-12-05
CN101268069A (zh) 2008-09-17
ATE537167T1 (de) 2011-12-15
TWI398436B (zh) 2013-06-11
TNSN08145A1 (en) 2009-07-14
IL190227A (en) 2015-05-31
US7851493B2 (en) 2010-12-14
BRPI0616465A2 (pt) 2011-06-21
PT1931660E (pt) 2012-10-30
WO2007039172A1 (en) 2007-04-12
DOP2006000205A (es) 2007-03-31
PE20070545A1 (es) 2007-06-15
US7834030B2 (en) 2010-11-16
EP1931660B1 (en) 2012-08-01
IL190228A0 (en) 2009-09-22
BRPI0616457A2 (pt) 2011-06-21
TW200811154A (en) 2008-03-01
MY148982A (en) 2013-06-28
AR056541A1 (es) 2007-10-10
KR20080048520A (ko) 2008-06-02

Similar Documents

Publication Publication Date Title
PE20070768A1 (es) Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
ATE288420T1 (de) Neuartige heterocyclische carboxamid-derivate
EA200900934A1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
AR055619A1 (es) Diaminopirimidinas como moduladores p2x2/3
PE20091096A1 (es) Compuestos organicos
EA200700441A1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
CR8595A (es) Inhibidor del dipeptidil-peptidasa
PE20070217A1 (es) Derivados de isoquinolona sustituidos con piperidinilo
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
PE20130242A1 (es) Derivados de isoxazolo-piridina
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
CO4820390A1 (es) Quinazolinas substituidas y bioisoesteres como inhibidores de la tirosina cinasa c-erb b- 2
NO20071843L (no) Substituerte anilinderivater
RU2008130878A (ru) Описание терапевтического средства против диабета
PE20080858A1 (es) Compuestos de n-aril pirazol y composiciones que los contienen
CO5060482A1 (es) Derivados terapeuticos de biarilo
PE107898A1 (es) Compuestos 1,3-diheterociclicos, inhibidores de metaloproteasa
PE20010491A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
GB0501964D0 (en) Chemical compounds
PE20060323A1 (es) Oxadiazolonas y procedimientos para su preparacion
CO5700746A2 (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
CO5611126A2 (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa
PE20081383A1 (es) Inhibidores benzoimidazolicos de trpv1
AR063518A1 (es) Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis

Legal Events

Date Code Title Description
FD Application declared void or lapsed